Skip to Main Content

Paper Details

Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer.
Clin Cancer Res
20
2019
Author NameAffiliation
Syed A HussainThe Clatterbridge Cancer Centre NHS Foundation Trust
Fred SaadCentre Hospitalier de l'Universite de Montreal
Roberta FerraldeschiAstex Therapeutics Ltd.
Penny FlohrThe Institute of Cancer Research and Royal Marsden Hospital
Paul WorkmanThe Institute of Cancer Research and Royal Marsden Hospital
Johann S de BonoThe Institute of Cancer Research and Royal Marsden Hospital
  • 1 - 6

Datasets

Release 1.2